PURPOSE: To determine the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of cediranib administered orally, once daily, continuously in children and adolescents with solid tumors. PATIENTS AND METHODS: Children and adolescents with refractory solid tumors, excluding primary brain tumors, were eligible. DLT at the starting dose of 12 mg/m(2)/d resulted in de-escalation to 8 mg/m(2)/d and subsequent re-escalation to 12 and 17 mg/m(2)/d. Pharmacokinetic and pharmacodynamic studies were performed during cycle 1. Response was evaluated using WHO criteria. RESULTS: Sixteen patients (median age, 15 years; range, 8 to 18 years) were evaluable for toxicity. DLTs (grade 3 nausea, vomiting, fatigue in one; hypertension and prolonged corrected QT interval in another) occurred in patients initially enrolled at 12 mg/m(2)/d. Subsequently, 8 mg/m(2)/d was well tolerated in three patients. An additional seven patients were enrolled at 12 mg/m(2)/d; one had DLT (grade 3 diarrhea). At 17 mg/m(2)/d, two of four patients had DLTs (grade 3 nausea; intolerable grade 2 fatigue). Non-dose-limiting toxicities included left ventricular dysfunction, elevated thyroid stimulating hormone, palmar-plantar erythrodysesthesia, weight loss, and headache. The MTD of cediranib was 12 mg/m(2)/d (adult fixed dose equivalent, 20 mg). At 12 mg/m(2)/d, the median area under the plasma concentration-time curve extrapolated to infinity (AUC(0-∞)) was 900 ng·h/mL, which is similar to adults receiving 20 mg. Objective responses were observed in patients with Ewing sarcoma, synovial sarcoma, and osteosarcoma. CONCLUSION: The recommended monotherapy dose of cediranib for children with extracranial solid tumors is 12 mg/m(2)/d administered orally, once daily, continuously. A phase II study is in development.
PURPOSE: To determine the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of cediranib administered orally, once daily, continuously in children and adolescents with solid tumors. PATIENTS AND METHODS: Children and adolescents with refractory solid tumors, excluding primary brain tumors, were eligible. DLT at the starting dose of 12 mg/m(2)/d resulted in de-escalation to 8 mg/m(2)/d and subsequent re-escalation to 12 and 17 mg/m(2)/d. Pharmacokinetic and pharmacodynamic studies were performed during cycle 1. Response was evaluated using WHO criteria. RESULTS: Sixteen patients (median age, 15 years; range, 8 to 18 years) were evaluable for toxicity. DLTs (grade 3 nausea, vomiting, fatigue in one; hypertension and prolonged corrected QT interval in another) occurred in patients initially enrolled at 12 mg/m(2)/d. Subsequently, 8 mg/m(2)/d was well tolerated in three patients. An additional seven patients were enrolled at 12 mg/m(2)/d; one had DLT (grade 3 diarrhea). At 17 mg/m(2)/d, two of four patients had DLTs (grade 3 nausea; intolerable grade 2 fatigue). Non-dose-limiting toxicities included left ventricular dysfunction, elevated thyroid stimulating hormone, palmar-plantar erythrodysesthesia, weight loss, and headache. The MTD of cediranib was 12 mg/m(2)/d (adult fixed dose equivalent, 20 mg). At 12 mg/m(2)/d, the median area under the plasma concentration-time curve extrapolated to infinity (AUC(0-∞)) was 900 ng·h/mL, which is similar to adults receiving 20 mg. Objective responses were observed in patients with Ewing sarcoma, synovial sarcoma, and osteosarcoma. CONCLUSION: The recommended monotherapy dose of cediranib for children with extracranial solid tumors is 12 mg/m(2)/d administered orally, once daily, continuously. A phase II study is in development.
Authors: Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544
Authors: Stephen R Wedge; Jane Kendrew; Laurent F Hennequin; Paula J Valentine; Simon T Barry; Sandra R Brave; Neil R Smith; Neil H James; Michael Dukes; Jon O Curwen; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Lyndsey L Kilburn; Sharon Barnett; Graham H P Richmond; Peter F Wadsworth; Mike Walker; Alison L Bigley; Sian T Taylor; Lee Cooper; Sarah Beck; Juliane M Jürgensmeier; Donald J Ogilvie Journal: Cancer Res Date: 2005-05-15 Impact factor: 12.701
Authors: Charles J Ryan; Walter M Stadler; Bruce Roth; Douglass Hutcheon; Shauna Conry; Thomas Puchalski; Charles Morris; Eric J Small Journal: Invest New Drugs Date: 2007-04-26 Impact factor: 3.850
Authors: Ursula A Matulonis; Suzanne Berlin; Percy Ivy; Karin Tyburski; Carolyn Krasner; Corrine Zarwan; Anna Berkenblit; Susana Campos; Neil Horowitz; Stephen A Cannistra; Hang Lee; Julie Lee; Maria Roche; Margaret Hill; Christin Whalen; Laura Sullivan; Chau Tran; Benjamin D Humphreys; Richard T Penson Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Manuela Schmidinger; Christoph C Zielinski; Ursula M Vogl; Andja Bojic; Marija Bojic; Christoph Schukro; Marquerite Ruhsam; Michael Hejna; Herwig Schmidinger Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Joachim Drevs; Patrizia Siegert; Michael Medinger; Klaus Mross; Ralph Strecker; Ute Zirrgiebel; Jan Harder; Hubert Blum; Jane Robertson; Juliane M Jürgensmeier; Thomas A Puchalski; Helen Young; Owain Saunders; Clemens Unger Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana Journal: Clin Cancer Res Date: 2012-11-08 Impact factor: 12.531
Authors: Stephan D Voss; Julia Glade-Bender; Sheri L Spunt; Steven G DuBois; Brigitte C Widemann; Julie R Park; Sarah E S Leary; Marvin D Nelson; Peter C Adamson; Susan M Blaney; Brenda Weigel Journal: Pediatr Blood Cancer Date: 2014-09-24 Impact factor: 3.167
Authors: Mark W Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C Turner; Clinton F Stewart; Marsha Moses; Roger J Packer; Regina Jakacki; Anu Banerjee; James M Boyett; Maryam Fouladi; Larry Kun Journal: Childs Nerv Syst Date: 2015-07-19 Impact factor: 1.475
Authors: AeRang Kim; Eva Dombi; Jeffrey Solomon; Elizabeth Fox; Frank M Balis; Brigitte C Widemann Journal: Clin Cancer Res Date: 2011-08-01 Impact factor: 12.531
Authors: Brigitte C Widemann; Aerang Kim; Elizabeth Fox; Sylvain Baruchel; Peter C Adamson; Ashish M Ingle; Julia Glade Bender; Michael Burke; Brenda Weigel; Diana Stempak; Frank M Balis; Susan M Blaney Journal: Clin Cancer Res Date: 2012-09-07 Impact factor: 12.531